<?xml version="1.0" encoding="UTF-8"?>
<!-- generator="wordpress/2.0" -->
<rss version="2.0" 
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	>

<channel>
	<title>Exubera Inhaled Insulin: Reported &#038; Suspected Risks for Diabetics</title>
	<link>http://www.exubera-risks.com</link>
	<description>Exubera inhaled insulin news and information on the FDA approved diabetes drug</description>
	<pubDate>Wed, 12 Nov 2008 03:57:37 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.0</generator>
	<language>en</language>
			<item>
		<title>Pfizer Selling Terre Haute, Ind. Exubera Inhaled Insulin Plant</title>
		<link>http://www.exubera-risks.com/2008/11/11/pfizer-selling-terre-haute-ind-exubera-inhaled-insulin-plant/</link>
		<comments>http://www.exubera-risks.com/2008/11/11/pfizer-selling-terre-haute-ind-exubera-inhaled-insulin-plant/#comments</comments>
		<pubDate>Wed, 12 Nov 2008 03:45:07 +0000</pubDate>
		<dc:creator>exuberar</dc:creator>
		
	<category>Uncategorized</category>
	<category>Exubera News</category>
	<category>Exubera: Type 1 Diabetes</category>
	<category>Exubera: Type 2 Diabetes</category>
	<category>Exubera - Pfizer</category>
	<category>Exubera Layoffs</category>
	<category>Exubera - Terre Haute</category>
		<guid isPermaLink="false">http://www.exubera-risks.com/2008/11/11/pfizer-selling-terre-haute-ind-exubera-inhaled-insulin-plant/</guid>
		<description><![CDATA[Pharmaceutical giant Pfizer is putting its Terre Haute, Indiana plant where the drug company manufactured Exubera inhaled insulin up for sale.  The plant totals 935 acres on roughly 560,000 square feet.
   According to the Terre Haute Tribune-Star, the Pfizer manufacturing facility has been in Terre Haute for sixty years since 1948.  [...]]]></description>
		<wfw:commentRSS>http://www.exubera-risks.com/2008/11/11/pfizer-selling-terre-haute-ind-exubera-inhaled-insulin-plant/feed/</wfw:commentRSS>
		</item>
		<item>
		<title>Pfizer, Nektar: Diabetics Who Used Exubera Developed Lung Cancer</title>
		<link>http://www.exubera-risks.com/2008/04/09/pfizer-nektar-diabetics-who-used-exubera-developed-lung-cancer/</link>
		<comments>http://www.exubera-risks.com/2008/04/09/pfizer-nektar-diabetics-who-used-exubera-developed-lung-cancer/#comments</comments>
		<pubDate>Wed, 09 Apr 2008 21:28:08 +0000</pubDate>
		<dc:creator>exuberar</dc:creator>
		
	<category>Exubera News</category>
	<category>Exubera Risks</category>
	<category>Exubera - FDA Approval</category>
	<category>Exubera: Physician Comments</category>
	<category>Exubera: Diabetes Treatment</category>
	<category>Exubera - Pulmonary Issues</category>
	<category>Exubera - Pfizer</category>
	<category>Exubera - Nektar</category>
	<category>Exubera: Smoking</category>
		<guid isPermaLink="false">http://www.exubera-risks.com/2008/04/09/pfizer-nektar-diabetics-who-used-exubera-developed-lung-cancer/</guid>
		<description><![CDATA[This blog has continued researching and reporting on potential Exubera inhaled insulin risks for more than two years.
Pfizer&#8217;s and Nektar&#8217;s announcements this morning that  6 of the 4,740 patients using Exubera in clinical studies developed lung cancer confirms what this blogger has been saying all along:

That it was foolish of the FDA to rush [...]]]></description>
		<wfw:commentRSS>http://www.exubera-risks.com/2008/04/09/pfizer-nektar-diabetics-who-used-exubera-developed-lung-cancer/feed/</wfw:commentRSS>
		</item>
		<item>
		<title>Pfizer Laying Off 660 Exubera Inhaled Insulin Workers From Terre Haute Plant</title>
		<link>http://www.exubera-risks.com/2008/01/28/pfizer-laying-off-660-exubera-inhaled-insulin-workers-from-terre-haute-plant/</link>
		<comments>http://www.exubera-risks.com/2008/01/28/pfizer-laying-off-660-exubera-inhaled-insulin-workers-from-terre-haute-plant/#comments</comments>
		<pubDate>Mon, 28 Jan 2008 21:11:06 +0000</pubDate>
		<dc:creator>exuberar</dc:creator>
		
	<category>Exubera News</category>
	<category>Exubera - Pfizer</category>
	<category>Exubera Layoffs</category>
	<category>Exubera - Terre Haute</category>
	<category>Ind.</category>
		<guid isPermaLink="false">http://www.exubera-risks.com/2008/01/28/pfizer-laying-off-660-exubera-inhaled-insulin-workers-from-terre-haute-plant/</guid>
		<description><![CDATA[Pfizer&#8217;s decision to halt Exubera inhaled insulin sales has led the layoff of 660 of the drug company&#8217;s workers at its Terre Haute, Indiana manufacturing facility.

The news was announced by Nat Ricciardi, president of Pfizer Global Manufacturing. Workers were informed that they would lose their jobs today, according to the Kalamazoo Gazette.
That will leave more [...]]]></description>
		<wfw:commentRSS>http://www.exubera-risks.com/2008/01/28/pfizer-laying-off-660-exubera-inhaled-insulin-workers-from-terre-haute-plant/feed/</wfw:commentRSS>
		</item>
		<item>
		<title>Novo-Nordisk Opts to Stop Inhaled Insulin Development</title>
		<link>http://www.exubera-risks.com/2008/01/15/novo-nordisk-opts-to-stop-inhaled-insulin-development/</link>
		<comments>http://www.exubera-risks.com/2008/01/15/novo-nordisk-opts-to-stop-inhaled-insulin-development/#comments</comments>
		<pubDate>Wed, 16 Jan 2008 00:39:59 +0000</pubDate>
		<dc:creator>exuberar</dc:creator>
		
	<category>Uncategorized</category>
	<category>Exubera News</category>
	<category>Exubera - Pfizer</category>
	<category>Diabetes Research</category>
	<category>Drug Litigation</category>
	<category>Novo-Nordisk</category>
		<guid isPermaLink="false">http://www.exubera-risks.com/2008/01/15/novo-nordisk-opts-to-stop-inhaled-insulin-development/</guid>
		<description><![CDATA[Danish diabetes drugmaker Novo-Nordisk has opted to halt further development of its AERx inhaled insulin.

The pharmaceutical company&#8217;s new decision comes shortly after it Pfizer and Novo settled their patent litigation of Pfizer&#8217;s Exubera inhaled insulin.
Novo&#8217;s AERX inhaled insulin was in Phase III trials when the decision was made.  The device previously that was previously [...]]]></description>
		<wfw:commentRSS>http://www.exubera-risks.com/2008/01/15/novo-nordisk-opts-to-stop-inhaled-insulin-development/feed/</wfw:commentRSS>
		</item>
		<item>
		<title>Novo-Nordisk, Pfizer Settle Patent Lawsuit Over Inhaled Insulin</title>
		<link>http://www.exubera-risks.com/2007/12/16/novo-nordisk-pfizer-settle-patent-lawsuit-over-inhaled-insulin/</link>
		<comments>http://www.exubera-risks.com/2007/12/16/novo-nordisk-pfizer-settle-patent-lawsuit-over-inhaled-insulin/#comments</comments>
		<pubDate>Sun, 16 Dec 2007 06:39:11 +0000</pubDate>
		<dc:creator>exuberar</dc:creator>
		
	<category>Exubera News</category>
	<category>Exubera - FDA Approval</category>
	<category>Exubera: Diabetes Treatment</category>
	<category>Exubera - Pfizer</category>
	<category>Exubera - Sales</category>
	<category>Drug Litigation</category>
	<category>Novo-Nordisk</category>
	<category>Aradigm Corp.</category>
		<guid isPermaLink="false">http://www.exubera-risks.com/2007/12/16/novo-nordisk-pfizer-settle-patent-lawsuit-over-inhaled-insulin/</guid>
		<description><![CDATA[Novo-Nordisk and Pfizer reportedly settled their patent litigation this week over Pfizer&#8217;s failed Exubera inhaled insulin and Novo&#8217;s AERx insulin that the Danish drugmaker has been developing with Aradigm Corp.

The litigation started just before Pfizer brought Exubera to market (after considerable delays), and continued for just over a year.
Novo claimed that Exubera infringed on a [...]]]></description>
		<wfw:commentRSS>http://www.exubera-risks.com/2007/12/16/novo-nordisk-pfizer-settle-patent-lawsuit-over-inhaled-insulin/feed/</wfw:commentRSS>
		</item>
		<item>
		<title>Go Insulin Injectable Insulin Ads From Sanofi - Spending $1.3B in Exubera Deal Money</title>
		<link>http://www.exubera-risks.com/2007/11/29/go-insulin-injectable-insulin-ads-from-sanofi-spending-13b-in-exubera-deal-money/</link>
		<comments>http://www.exubera-risks.com/2007/11/29/go-insulin-injectable-insulin-ads-from-sanofi-spending-13b-in-exubera-deal-money/#comments</comments>
		<pubDate>Thu, 29 Nov 2007 17:55:29 +0000</pubDate>
		<dc:creator>exuberar</dc:creator>
		
	<category>Exubera News</category>
	<category>Exubera - Pfizer</category>
	<category>Exubera - Nektar</category>
	<category>Exubera: Sanofi-Aventis</category>
	<category>Exubera - Sales</category>
	<category>Exubera Ads</category>
	<category>Apidra</category>
	<category>Lantus</category>
		<guid isPermaLink="false">http://www.exubera-risks.com/2007/11/29/go-insulin-injectable-insulin-ads-from-sanofi-spending-13b-in-exubera-deal-money/</guid>
		<description><![CDATA[After scoring a $1.3 billion deal selling Pfizer all of its rights to market Exubera inhaled insulin, Sanofi-Aventis probably laughed all the way to the bank when Pfizer pulled the ridiculously unprofitable diabetes drug from the market.
That&#8217;s why Sanofi&#8217;s latest ad campaign for injectable insulin has a timely &#8220;I told you so&#8221; quality to it. [...]]]></description>
		<wfw:commentRSS>http://www.exubera-risks.com/2007/11/29/go-insulin-injectable-insulin-ads-from-sanofi-spending-13b-in-exubera-deal-money/feed/</wfw:commentRSS>
		</item>
		<item>
		<title>Alkeremes CEO Warns AIR Inhaled Insulin With Lilly May Affect Lung Function</title>
		<link>http://www.exubera-risks.com/2007/10/23/alkeremes-ceo-warns-air-inhaled-insulin-with-lilly-may-affect-lung-function/</link>
		<comments>http://www.exubera-risks.com/2007/10/23/alkeremes-ceo-warns-air-inhaled-insulin-with-lilly-may-affect-lung-function/#comments</comments>
		<pubDate>Tue, 23 Oct 2007 22:09:48 +0000</pubDate>
		<dc:creator>exuberar</dc:creator>
		
	<category>Exubera News</category>
	<category>Exubera Risks</category>
	<category>Exubera: Physician Comments</category>
	<category>Exubera - Pulmonary Issues</category>
	<category>Eli Lilly &#038; Co.</category>
	<category>Alkermes</category>
		<guid isPermaLink="false">http://www.exubera-risks.com/2007/10/23/alkeremes-ceo-warns-air-inhaled-insulin-with-lilly-may-affect-lung-function/</guid>
		<description><![CDATA[Less than a week after Pfizer decided to stop selling Exubera inhaled insulin, the Chairman of rival drug developer Alkermes cautioned that it&#8217;s AIR inhaled insulin could also affect diabetics&#8217; lung function.

Richard Pops, Chairman of Cambridge, Mass.-based Alkeremes, told Reuters that the inhaled insulin that the company is jointly developing with Eli Lilly &#038; Co., [...]]]></description>
		<wfw:commentRSS>http://www.exubera-risks.com/2007/10/23/alkeremes-ceo-warns-air-inhaled-insulin-with-lilly-may-affect-lung-function/feed/</wfw:commentRSS>
		</item>
		<item>
		<title>Pfizer Stops Exubera Inhaled Insulin Sales, Citing Financial Reasons</title>
		<link>http://www.exubera-risks.com/2007/10/21/pfizer-stops-exubera-inhaled-insulin-sales-citing-financial-reasons/</link>
		<comments>http://www.exubera-risks.com/2007/10/21/pfizer-stops-exubera-inhaled-insulin-sales-citing-financial-reasons/#comments</comments>
		<pubDate>Mon, 22 Oct 2007 00:01:45 +0000</pubDate>
		<dc:creator>exuberar</dc:creator>
		
	<category>Exubera News</category>
	<category>Exubera: Physician Comments</category>
	<category>Exubera: Diabetes Treatment</category>
	<category>Exubera: Insulin &#038; Drug Sales</category>
	<category>Exubera - Sales</category>
	<category>Exubera Cost</category>
	<category>Exubera Marketing</category>
		<guid isPermaLink="false">http://www.exubera-risks.com/2007/10/21/pfizer-stops-exubera-inhaled-insulin-sales-citing-financial-reasons/</guid>
		<description><![CDATA[It&#8217;s official: Pfizer&#8217;s Exubera inhaled insulin experiment is over.
Sales of the diabetes drug were a complete failure. Some might even think of them as non-existent, considering that Pfizer paid Sanofi-Aventis $1.3 billion to acquire exclusive worldwide rights to market the insulin, yet only generated $4 million in sales for Q2 2007.   The company&#8217;s website [...]]]></description>
		<wfw:commentRSS>http://www.exubera-risks.com/2007/10/21/pfizer-stops-exubera-inhaled-insulin-sales-citing-financial-reasons/feed/</wfw:commentRSS>
		</item>
	</channel>
</rss>
